Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

2,000

Employees2,000

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

2,000

Employees2,000

NBIX Key Statistics

Market cap

16.06B

Market cap16.06B

Price-Earnings ratio

24.34

Price-Earnings ratio24.34

Dividend yield

—

Dividend yield—

Average volume

1.18M

Average volume1.18M

High today

$161.39

High today$161.39

Low today

$159.32

Low today$159.32

Open price

$161.17

Open price$161.17

Volume

210.73K

Volume210.73K

52 Week high

$169.57

52 Week high$169.57

52 Week low

$122.14

52 Week low$122.14

Stock Snapshot

As of today, Neurocrine(NBIX) shares are valued at $159.77. The company's market cap stands at 16.06B, with a P/E ratio of 24.34.

During the trading session on 2026-06-22, Neurocrine(NBIX) shares reached a daily high of $161.39 and a low of $159.32. At a current price of $159.77, the stock is +0.3% higher than the low and still -1.0% under the high.

Trading activity shows a volume of 210.73K, compared to an average daily volume of 1.18M.

The stock's 52-week range extends from a low of $122.14 to a high of $169.57.

NBIX News

Simply Wall St 2h

What Neurocrine Biosciences's New CRENESSITY CAH Data Means For Shareholders

Earlier in June 2026, Neurocrine Biosciences reported new data at ENDO 2026 showing CRENESSITY (crinecerfont) delivered strong hormonal control and glucocortico...

Simply Wall St 3d

Neurocrine Biosciences Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data

Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficie...

TipRanks 5d

Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors

Neurocrine Biosciences (NBIX) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premi...

Analyst ratings

88%

of 32 ratings

Buy

87.5%

Hold

12.5%

Sell

More NBIX News

TipRanks 6d

Neurocrine: Pipeline De-Risking With Positive Crenessity and Vykat XR Data; Buy Rating Reiterated, $246 Price Target Unchanged

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Neurocrine, retaining the price target of $246.00. Unlock powerful investing tools and data-driven...

TipRanks 7d

Neurocrine presents first retrospective case series of Crenessity

Neurocrine (NBIX) Biosciences announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adren...

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.